Yasemin DADAS | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Yasemin Dadas 
Nigde Omer Halisdemir University, Turkey
Yasemin Dadas
Affiliation Department of Obstetrics and Gynecology, Faculty of Medicine, Nigde Omer Halisdemir University
Country Turkey
Scopus ID 60163710500
Documents 2
Citations 3
h-index 1
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research

Yasemin Dadas is a researcher and academic physician affiliated with the Department of Obstetrics and Gynecology, Faculty of Medicine, Nigde Omer Halisdemir University, Turkey. Publicly available academic records associate her research with obstetrics and gynecology and with oncology-related questions, including fertility preservation in women with pelvic gynecologic malignancies. Her institutional affiliation is also listed in the academic staff records of Nigde Omer Halisdemir University. [1] [2]

Abstract

Yasemin Dadas is affiliated with the Department of Obstetrics and Gynecology at Nigde Omer Halisdemir University in Turkey. Her documented scholarly work includes research involving reproductive medicine and gynecologic oncology. A 2026 systematic review co-authored by Dadas examines fertility preservation strategies for women with pelvic gynecologic malignancies and considers the integration of oncologic surgery, chemotherapy, radiotherapy, and multidisciplinary care. [2] Her publication record also includes research concerning progesterone protocols used in frozen-thawed embryo transfer preparation. [3]

Keywords

Yasemin Dadas; Cancer Cell Biology; gynecologic oncology; pelvic gynecologic malignancies; fertility preservation; reproductive medicine; obstetrics and gynecology; oncology research; multimodal cancer care; Nigde Omer Halisdemir University.

Introduction

Research at the intersection of gynecology, reproductive medicine, and oncology addresses clinical questions that affect both cancer treatment and reproductive potential. In pelvic gynecologic malignancies, fertility preservation can form part of multidisciplinary treatment planning, particularly when surgery and subsequent anticancer therapies may affect reproductive function. Dadas’ published work contributes to this clinical research area through a systematic review focused on fertility preservation strategies in women undergoing multimodal oncologic treatment. [2]

Research Profile

The available academic record places Yasemin Dadas within obstetrics and gynecology, with published research spanning reproductive medicine and subjects relevant to gynecologic oncology. Her institutional profile identifies her as a faculty member in the Department of Obstetrics and Gynecology at Nigde Omer Halisdemir University. [1]

Research Contributions

A principal documented contribution is the systematic examination of fertility preservation strategies for women with pelvic gynecologic malignancies. The review evaluates approaches used around pelvic oncologic surgery and subsequent treatment and emphasizes the need to consider reproductive outcomes alongside oncologic management. [2]

Publications

The two publications listed above are independently identifiable through scholarly bibliographic sources and correspond with the supplied Scopus document count. The 2026 systematic review is indexed in PubMed and PubMed Central, while the 2025 Biomedicines article is also indexed in PubMed. [2] [3]

Research Impact

The supplied bibliometric profile reports 2 documents, 3 citations, and an h-index of 1 for Scopus Author ID 60163710500. These indicators describe the citation record associated with the supplied profile and should be interpreted in relation to publication age, field-specific citation patterns, and the size of the documented publication portfolio.

Award Suitability

For an academic recognition profile under the Innovative Research Award, the documented record provides identifiable evidence of research activity in obstetrics and gynecology, reproductive medicine, and gynecologic oncology. In particular, the systematic review on fertility preservation in pelvic gynecologic malignancies directly addresses a cancer-care research question and incorporates multiple dimensions of oncologic treatment. [2]

Conclusion

Yasemin Dadas has a documented academic profile at Nigde Omer Halisdemir University in Turkey, with research spanning obstetrics and gynecology, reproductive medicine, and gynecologic oncology. Her published work includes a systematic review addressing fertility preservation in women with pelvic gynecologic malignancies and a study of progesterone protocols for frozen-thawed embryo transfer. [2] [3]

1.Scopus Author Profile — Yasemin Dadas, Author ID 60163710500

2. Comparison of Different Progesterone Protocols for Luteal Support

3.  International Research Awards on Oncology and Cancer Research — Award Website

References

1.Niğde Ömer Halisdemir Üniversitesi. (n.d.). Faculty of Medicine — Academic Staff / Department of Surgical Medical Sciences. The institutional listing        identifies Yasemin Dadaş within the Department of Obstetrics and Gynecology.
    https://www.ohu.edu.tr/facultyofmedicine/academic-staff2

2.Dadas, Y., Oner, G., Karaman, E., Ayan, D., Doganay, H. N., Bayram, E., Tunca Sanlier, N., & Kulular, B. (2026). Fertility Preservation Strategies in          Women with Pelvic Gynecologic Malignancies Undergoing Multimodal Oncologic Treatment: A Systematic Review. Cancers, 18(7), 1142.
    https://doi.org/10.3390/cancers18071142

3.Oner, G., Karaman, E., Kulular, B., Dadas, Y., & Doganay, H. N. (2025). Comparison of Different Progesterone Protocols for Luteal Support in Frozen-      Thawed Embryo Transfer Preparation. Biomedicines, 13(10), 2487.
     https://dergipark.org.tr/tr/pub/@yasemin-dadas

4.Elsevier. (n.d.). Scopus Author Details: Yasemin Dadas, Author ID 60163710500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=60163710500

5.International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

 

Celal Özbek Çakır | chemotherapy | Innovative Research Award

Published on by Oncology

Innovative Research Award

Celal Özbek Çakır
Karamanoğlu Mehmet Bey University, Turkey

Celal Özbek Çakır
Affiliation Karamanoğlu Mehmet Bey University
Country Turkey
Subject Area Chemotherapy
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-3618-6033

Celal Özbek Çakır is a researcher affiliated with Karamanoğlu Mehmet Bey University in Turkey whose stated subject area is chemotherapy. This recognition profile presents the researcher in the context of the Innovative Research Award associated with the International Research Awards on Oncology and Cancer Research. The profile is based on the identifying and affiliation information supplied for the award record, together with persistent researcher-identification information available through ORCID. [1]

Abstract

This academic recognition profile concerns Celal Özbek Çakır of Karamanoğlu Mehmet Bey University, Turkey, with chemotherapy identified as the principal subject area. The profile is associated with the Innovative Research Award within the International Research Awards on Oncology and Cancer Research. The researcher is identified through the ORCID persistent identifier 0000-0002-3618-6033, which provides a standardized mechanism for distinguishing researchers and connecting their scholarly activities with an individual record. [2]

Keywords

Keywords: chemotherapy, oncology research, cancer research, cancer treatment, anticancer therapy, therapeutic research, drug response, oncology pharmacology, innovative research, translational oncology, Karamanoğlu Mehmet Bey University, Turkey, Innovative Research Award.

Introduction

Chemotherapy is an established component of cancer treatment research and encompasses the investigation and clinical application of medicines that can interfere with the growth, division, or survival of cancer cells. Contemporary oncology research also examines how therapeutic approaches can be optimized through combination strategies, treatment sequencing, biomarker-informed approaches, and improved management of treatment-related effects. The National Cancer Institute describes chemotherapy as a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. [3]

Research Profile

Celal Özbek Çakır is affiliated with Karamanoğlu Mehmet Bey University in Turkey. The supplied academic profile identifies chemotherapy as the relevant subject area and associates the researcher with the Innovative Research Award. The researcher’s ORCID iD is 0000-0002-3618-6033. ORCID identifiers are persistent identifiers designed to distinguish researchers and support reliable attribution of scholarly work across systems. [2]

Research Contributions

The stated research area of chemotherapy places the profile within cancer-treatment research. Potential contribution areas in this domain include the study of anticancer agents, mechanisms of drug action, treatment resistance, combination therapies, therapeutic optimization, and strategies for improving the safety or effectiveness of cancer treatment. However, individual contribution claims require supporting publication or institutional evidence and should not be attributed to the researcher without verification.

Publications

A verified publication list was not supplied as part of the profile data. Consequently, specific articles, journal titles, publication dates, citation counts, and DOI records are not attributed to Celal Özbek Çakır in this section. A complete publication assessment should be conducted using the researcher’s ORCID record and authoritative bibliographic databases, with author identity and affiliation checked for each publication. [1] [2]

Research Impact

Research impact in oncology may be reflected through several forms of scholarly and practical contribution, including peer-reviewed publications, citation and reuse of research findings, methodological advances, collaborative research, translational applications, and contributions to evidence used in cancer treatment. Citation counts and h-index values can be useful descriptive indicators, but they should be interpreted in relation to discipline, career stage, database coverage, and publication history.

Award Suitability

The Innovative Research Award is presented in the context of the International Research Awards on Oncology and Cancer Research. Based on the supplied profile information, the researcher’s stated subject area of chemotherapy is directly situated within cancer-treatment research. This establishes topical relevance to an oncology-focused research recognition program.

Conclusion

Celal Özbek Çakır is identified in the supplied award profile as a researcher affiliated with Karamanoğlu Mehmet Bey University, Turkey, with chemotherapy as the stated subject area and ORCID iD 0000-0002-3618-6033. The profile connects the researcher with the Innovative Research Award under the International Research Awards on Oncology and Cancer Research. [2]

References

  1. 1.Elsevier. (n.d.): Abstract and citation database and author profiles. Scopus.
    https://www.scopus.com/
  2. 2.ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.
    https://orcid.org/0000-0002-3618-6033
  3. 3.National Cancer Institute.(n.d.).Chemotherapy to Treat Cancer. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/chemotherapy
  4. 4.International DOI Foundation. (n.d.). DOI Handbook. International DOI Foundation.
    https://www.doi.org/the-identifier/resources/factsheets/doi-handbook
      5. International Research Awards on Oncology and Cancer Research
       https://doi.org/10.1179/016164107X159225

Rabbani Syed | Pharmaco-Oncology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Rabbani Syed
King Saud University, Saudi Arabia

Rabbani Syed
Affiliation King Saud University
Country Saudi Arabia
Scopus ID 35751491100
Documents 95
Citations 1,703
h-index 21
Subject Area Pharmaco-Oncology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4695-0645

The Innovative Research Award recognizes research activity that contributes to the development of new knowledge, methodologies, or applications within a defined academic discipline. This profile presents the available research information associated with Rabbani Syed of King Saud University, Saudi Arabia, in the context of the International Research Awards on Oncology and Cancer Research.

Abstract

This academic recognition profile documents the supplied research information of Rabbani Syed, affiliated with King Saud University in Saudi Arabia. The researcher is associated with the subject area of Pharmaco-Oncology and has been proposed in connection with the Innovative Research Award. The available bibliometric information includes 95 documents, 1,703 citations, and an h-index of 21. These indicators offer a measurable description of scholarly activity but do not, by themselves, establish the originality or practical effectiveness of individual studies. Further evaluation requires examination of publications, research methods, and documented contributions.

Keywords

Keywords: Innovative Research Award, Rabbani Syed, King Saud University, Saudi Arabia, Pharmaco-Oncology, cancer research, oncology, pharmaceutical research, bibliometrics, scholarly publications, therapeutic research, research recognition.

Introduction

Pharmaco-Oncology encompasses research involving medicines, drug mechanisms, therapeutic development, and pharmacological strategies relevant to cancer care. Innovation in this field may involve the discovery of candidate compounds, investigation of drug responses, improvements in drug-delivery systems, or the evaluation of treatment-related biological mechanisms. Research recognition in this area requires consideration of the scientific question, methodological rigor, reproducibility, and potential relevance to oncology. [2]

Research Profile

Rabbani Syed is identified in the supplied information as a researcher affiliated with King Saud University, Saudi Arabia. The provided Scopus author identifier is 35751491100, while the ORCID identifier is 0000-0003-4695-0645. The supplied profile statistics indicate 95 documents, 1,703 citations, and an h-index of 21. These figures should be interpreted with reference to the date of retrieval and the specific author record. [1]

Research Contributions

The supplied subject classification places the researcher within Pharmaco-Oncology. However, detailed information about specific research projects, experimental findings, patented technologies, clinical investigations, or methodological innovations has not been provided. Consequently, individual contributions cannot be independently described in detail. A comprehensive assessment would examine the originality of the research questions, the quality of the evidence, and the relevance of reported findings to oncology and pharmaceutical science. [3]

Publications

The supplied information reports a total of 95 documents associated with the researcher’s academic record. A complete publication list, including article titles, journals, publication dates, co-authors, and digital object identifiers, was not supplied for this profile. The Scopus author record may provide a starting point for examining indexed publications and related citation information. Publication-level verification is necessary before attributing specific scientific findings or research achievements.

Research Impact

The reported citation count of 1,703 and h-index of 21 provide quantitative indicators of the researcher’s documented scholarly visibility. Citation measures can assist in describing patterns of academic attention, but they may be influenced by publication age, disciplinary practices, collaboration patterns, and database coverage. They should therefore be considered alongside qualitative evidence, including research reproducibility, scientific influence, and documented applications. [4]

Award Suitability

The Innovative Research Award is associated with research that demonstrates originality and meaningful advancement within a relevant field. The supplied affiliation, subject area, publication count, citation count, and h-index provide contextual information for an academic review. A formal award assessment should additionally consider the nominee’s documented innovations, supporting publications, research significance, and compliance with the event’s eligibility criteria. The available information alone does not establish the outcome of an award evaluation.

Conclusion

Rabbani Syed is identified in the supplied data as a King Saud University researcher working in the subject area of Pharmaco-Oncology. The reported record includes 95 documents, 1,703 citations, and an h-index of 21. These metrics summarize selected aspects of scholarly activity. Further information about research innovations, individual publications, and documented scientific outcomes would be required to develop a more comprehensive academic assessment in relation to the Innovative Research Award.

References

  1. Elsevier. (n.d.). Scopus author details: Rabbani Syed, Author ID 35751491100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=35751491100
  2. National Cancer Institute. (n.d.). Drug therapy and cancer treatment research. National Cancer Institute.https://www.cancer.gov/about-cancer/treatment/types
  3. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.https://doi.org/10.1158/2159-8290.CD-21-1059
  4. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.https://doi.org/10.1073/pnas.0507655102
  5. ORCID. (n.d.). ORCID: Connecting research and researchers. ORCID.https://orcid.org/0000-0003-4695-0645

Rahul Kota | Cancer Genetics | Young Scientist Award

Published on by Oncology

Young Scientist Award

Rahul Kota
QIS College of Pharmacy, India

Rahul Kota
Affiliation QIS College of Pharmacy
Country India
Subject Area Cancer Genetics
Event International Research Awards on Oncology and Cancer Research
ORCID 0009-0007-0528-4865

Rahul Kota is affiliated with QIS College of Pharmacy in India and is identified with the subject area of cancer genetics. Cancer genetics examines the relationship between genetic variation, genomic alterations, inherited susceptibility, and the development or progression of cancer. The field contributes to understanding molecular mechanisms of disease and can support the development of improved approaches to cancer risk assessment, diagnosis, classification, and treatment. [1]

Abstract

This academic recognition profile concerns Rahul Kota of QIS College of Pharmacy, India, whose stated subject area is Cancer Genetics. Cancer genetics is an interdisciplinary area within biomedical and oncology research that investigates genetic and genomic factors associated with cancer initiation, susceptibility, progression, and therapeutic response. Modern cancer research increasingly integrates molecular genetics with genomic technologies to characterize tumor biology and identify clinically relevant alterations. [1]

Keywords

Cancer Genetics; cancer genomics; oncology research; genetic variation; tumor genetics; molecular oncology; genomic medicine; cancer susceptibility; precision oncology; biomedical research; young scientist; cancer research.

Introduction

Cancer is fundamentally a disease involving alterations to cellular genetic and regulatory processes. Genetic changes may arise through inherited variation or accumulate during an individual’s lifetime, with combinations of genomic alterations influencing tumor development and biological behavior. Large-scale genomic studies have demonstrated substantial molecular diversity among cancers, supporting the classification of tumors according to their underlying molecular characteristics. [2]

Research Profile

Rahul Kota is associated with QIS College of Pharmacy and has been identified for this profile under the research area of Cancer Genetics. The supplied researcher identifier is ORCID 0009-0007-0528-4865, providing a persistent digital identifier that can be used to distinguish a researcher from other individuals with similar names.

Research Contributions

Within cancer genetics, research contributions may encompass investigation of inherited and acquired genetic alterations, molecular mechanisms of tumor development, genetic determinants of cancer susceptibility, genomic characterization of tumors, and the interpretation of molecular information for oncology applications. Cancer-associated genetic alterations can affect pathways involved in cell proliferation, DNA repair, apoptosis, and other processes relevant to malignant transformation. [3]

Publications

No verified publication list was supplied for this profile. Consequently, individual publications, journal articles, citation counts, and DOI records are not attributed to Rahul Kota in order to avoid conflating publications by researchers with similar names.For a formal academic evaluation, publications should be verified through authoritative scholarly records and matched using persistent identifiers, institutional affiliation, subject area, authorship information, and DOI metadata where available.

Research Impact

Cancer genetics has substantial relevance to contemporary oncology because genomic information can improve understanding of disease heterogeneity and provide a foundation for molecularly informed clinical research. The identification and interpretation of cancer-associated alterations have become important components of translational oncology and precision-medicine research. [2] [3]

Award Suitability

The Young Scientist Award is presented here within the context of the International Research Awards on Oncology and Cancer Research. Rahul Kota’s supplied affiliation with QIS College of Pharmacy and stated specialization in Cancer Genetics establish a subject-area connection with oncology and cancer research.Based solely on the supplied information, the profile demonstrates thematic alignment with the award’s oncology research scope. A complete award assessment would additionally require verification of eligibility criteria, research outputs, publication record, originality of contributions, and other evaluation requirements established by the award program.

Conclusion

Rahul Kota, affiliated with QIS College of Pharmacy in India, is profiled within the field of Cancer Genetics for consideration under the Young Scientist Award associated with the International Research Awards on Oncology and Cancer Research. The available information supports a clear subject-area relationship with oncology research. Further assessment of scholarly achievement should be based on verified publication, citation, authorship, and research-impact evidence.

References

1. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46.
        https://doi.org/10.1158/2159-8290.CD-21-1059

2. The Cancer Genome Atlas Research Network. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 45, 1113–  1120.                         https://doi.org/10.1038/ng.2764

3. National Cancer Institute. (n.d.). Precision Medicine in Cancer. National Institutes of Health.
         https://www.cancer.gov/research/infrastructure/precision-medicine

4. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., & Kinzler, K. W. (2013). Cancer Genome Landscapes. Science, 339(6127),          1546–1558.
         https://doi.org/10.1126/science.1235122

5. ORCID. (n.d.). ORCID: Connecting Research and Researchers.
          https://orcid.org/

Eisa Mohammadi | Oncology Nursing | Best Researcher Award

Published on by Oncology

Best Researcher Award

Eisa Mohammadi
Tarbiat Modares University, Iran
Eisa Mohammadi
Affiliation Tarbiat Modares University
Country Iran
Scopus ID 6506581702
Documents 308
Citations 5,456
h-index 37
Subject Area Oncology Nursing
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

Eisa Mohammadi is an academic researcher affiliated with Tarbiat Modares University in Iran whose scholarly activities are associated with nursing, patient care, clinical practice, and health-related qualitative research. His publication record includes investigations addressing clinical nursing practice, patient experiences, supportive care, professional competencies, and psychosocial dimensions of health care.  [1]

Abstract

This academic recognition profile examines the research record of Eisa Mohammadi in relation to the Best Researcher Award within the International Research Awards on Oncology and Cancer Research. His work reflects a nursing-centered research perspective incorporating patient experiences, clinical interventions, care quality, symptom assessment, psychosocial support, and professional nursing practice. [2]

Keywords

Oncology nursing; cancer care; nursing research; patient-centered care; chemotherapy; quality of life; clinical nursing; supportive care; symptom management; psychosocial oncology; spiritual care; qualitative research; nursing intervention; patient experience.

Introduction

Oncology nursing integrates clinical knowledge with symptom management, education, psychological support, communication, rehabilitation, and quality-of-life assessment. Research in this field increasingly addresses not only disease treatment but also how patients and families experience illness and care. Mohammadi’s nursing scholarship demonstrates engagement with these human and clinical dimensions. A study examining a healing program for patients receiving chemotherapy, for example, investigated quality-of-life outcomes and identified Mohammadi with the Department of Nursing at Tarbiat Modares University. [2]

Research Profile

The supplied Scopus metrics identify Mohammadi with 308 documents, 5,456 citations, and an h-index of 37. These bibliometric indicators describe a substantial publication record and recurring citation of his scholarly output. His research profile spans nursing practice and patient-focused health research, with particular relevance to qualitative investigation, clinical care processes, professional nursing competencies, and supportive interventions. Independent bibliographic records also associate Eisa Mohammadi with Tarbiat Modares University and a broad body of nursing scholarship. [1]

Research Contributions

Mohammadi’s contributions illustrate how nursing research can strengthen evidence-based clinical practice. Research on pain assessment investigated organizational and educational approaches for improving nurses’ assessment skills, emphasizing the importance of structured clinical competency development. [3] Other work has examined spiritual care as a nursing concept, an area relevant to comprehensive cancer care because serious illness frequently introduces existential, emotional, cultural, and spiritual concerns that influence patient experiences and supportive-care requirements. [4]

Publications

Selected publications demonstrate methodological and clinical diversity. Farahani, Alhani, and Mohammadi evaluated the establishment of a pain committee and its influence on pediatric nurses’ pain-assessment skills in the International Journal of Nursing Practice. [3] Samari, Mohammadi, and Ahmadi reported on a healing program and quality of life among chemotherapy patients. [2] Mohammadi has also contributed to qualitative research examining patient experiences and barriers affecting engagement with health-care services. [5]

Research Impact

The reported citation count and h-index indicate continuing scholarly visibility across nursing and health-care literature. Research impact in nursing is additionally reflected through applicability to professional practice, patient safety, symptom assessment, supportive care, and educational interventions. Mohammadi’s work addresses several of these dimensions, combining empirical investigation with clinically meaningful questions.

Award Suitability

Assessment for a Best Researcher Award may reasonably consider research productivity, citation influence, methodological contribution, continuity of scholarship, and relevance to the award field. Based on the supplied bibliometric indicators and identifiable publications, Mohammadi presents a profile characterized by extensive scholarly activity and nursing-focused clinical research.

Conclusion

Eisa Mohammadi’s academic profile represents sustained engagement with nursing science, clinical practice, patient experience, and supportive health care. His research record includes contributions relevant to cancer treatment experiences, quality of life, nursing assessment, and holistic care. Within an oncology-focused academic recognition framework, these contributions establish a clear interdisciplinary relationship between nursing research and comprehensive cancer care.

References

1.Elsevier. (n.d.). Scopus author details: Eisa Mohammadi, Author ID 6506581702. Scopus.
        https://www.scopus.com/pages/authors/6506581702

2.Farahani, P. V., Alhani, F., & Mohammadi, E. (2014). Effect of establishing pain committee on the pain assessment skills of paediatric nurses. International          Journal of Nursing Practice, 20(5), 499–509:
        https://doi.org/10.1111/ijn.12191

3.Ramezani, M., Ahmadi, F., Mohammadi, E., & Kazemnejad, A. (2014). Spiritual care in nursing: A concept analysis. International Nursing Review, 61, 211–           219. Wiley Online Library.

       https://onlinelibrary.wiley.com/

4.Saki, M., Kermanshahi, S. M. K., Mohammadi, E., & Mohraz, M. (2015). Explaining the hindering factors for accepting the disease, a barrier for the                       HIV/AIDS patients to seek treatment:

       https://doi.org/10.4103/2345-5756.231401

5.National Library of Medicine. (n.d.). PubMed record: Effect of establishing pain committee on the pain assessment skills of paediatric nurses. PubMed,                 PMID 24124759.

       https://pubmed.ncbi.nlm.nih.gov/24124759/

LEANDRO RESENDE | Oncology and precision medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

LEANDRO RESENDE
Rede Dor

LEANDRO RESENDE
Affiliation Rede Dor
Country Brazil
Scopus ID 57188977624
Documents 5
Citations 35
h-index 3
Subject Area Oncology and precision medicine
Event International Research Awards on Oncology and Cancer Research
Scopus Author Profile

LEANDRO RESENDE is a researcher affiliated with Rede Dor in Brazil whose documented scholarly profile is associated with oncology and precision medicine.The Innovative Research Award profile presents this research activity within the broader context of contemporary cancer science, where molecular characterization, individualized treatment strategies, biomarkers, and evidence-based clinical decision-making increasingly intersect. Precision oncology seeks to connect biological information with clinically meaningful therapeutic choices. [1]

Abstract

The Innovative Research Award profile recognizes the research record of LEANDRO RESENDE, affiliated with Rede Dor, Brazil, in the field of oncology and precision medicine. The documented Scopus profile reports five scholarly documents, 35 citations, and an h-index of 3. [1] These indicators provide a bibliometric snapshot of published research and citation activity.Within modern oncology, precision medicine emphasizes the integration of molecular, clinical, and pathological information to support more individualized approaches to cancer investigation and treatment.

Keywords

  • Innovative Research Award
  • Oncology
  • Precision Medicine
  • Cancer Research
  • Biomedical Research
  • Research Impact

Introduction

Cancer research increasingly depends on interdisciplinary approaches that connect molecular biology, clinical medicine, pathology, genomics, and computational analysis. Precision medicine has developed as an important framework for identifying biological differences between tumors and using those differences to inform research and therapeutic strategies. [3]Against this background, researchers working across oncology contribute to a continually expanding evidence base.

Research Profile

LEANDRO RESENDE is affiliated with Rede Dor in Brazil and is represented in Scopus under Author ID 57188977624. The supplied profile records five documents, 35 citations, and an h-index of 3. [1] The stated subject area is oncology and precision medicine, placing the research profile within a clinically and scientifically significant field.

Research Contributions

Contemporary cancer frameworks emphasize multiple interacting characteristics of malignant disease, including genomic instability, cellular signaling, immune interactions, and the tumor microenvironment. [3]The documented bibliometric record offers measurable evidence of scholarly dissemination, while the specific scientific significance of individual publications should be evaluated through their methods, findings, citations, and subsequent use by other researchers.

Publications

The supplied Scopus record identifies five documents associated with the researcher. [1] Because complete publication titles, journal information, publication years, and DOI identifiers were not supplied with the profile data, this article does not assign specific publication details that cannot be independently established from the provided record.

Research Impact

The reported total of 35 citations indicates that the indexed documents have been cited within the scholarly literature. The h-index of 3 further describes a citation distribution in which at least three documents have each received at least three citations, subject to the indexing and counting methodology used by the database. [1]Citation metrics are useful descriptive measures but do not independently determine scientific quality or societal impact.

Award Suitability

The supplied research profile is aligned thematically with an award focused on oncology and cancer research because the stated subject area is oncology and precision medicine. The documented publication and citation record provides an objective basis for describing established scholarly activity. [1]Final award assessment should be based on the organizer’s published eligibility criteria, submitted evidence, peer or committee evaluation, and the originality and significance of the candidate’s research.

Conclusion

LEANDRO RESENDE’s supplied academic profile documents research activity associated with Rede Dor, Brazil, and the fields of oncology and precision medicine. The Scopus record reports five documents, 35 citations, and an h-index of 3, providing a concise bibliometric description of the researcher’s indexed scholarly output. [1]The Innovative Research Award profile places these activities within the wider development of precision oncology and evidence-based cancer research.

References

  1. Elsevier. (n.d.). Scopus author details: LEANDRO RESENDE, Author ID 57188977624. Scopus.
    https://www.scopus.com/pages/authors/57188977624
  2. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment. National Cancer Institute.
    https://www.cancer.gov/about-cancer/treatment/types/precision-medicine
  3. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cell, 185(1), 31–41. DOI: 10.1016/j.cell.2021.12.029.
    https://doi.org/10.1016/j.cell.2021.12.029
  4. Ashley, E. A. (2016). Towards precision medicine. Nature Reviews Genetics, 17, 507–522. DOI: 10.1038/nrg.2016.86.
    https://doi.org/10.1038/nrg.2016.86
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Official Award Website.
    https://oncology.pencis.com/

Safeena Kulsum | Cancer Biomarkers | Innovative Research Award

Published on by Oncology

Innovative Research Award

Safeena Kulsum
Narayana Hrudayalaya Ltd, India

Safeena Kulsum
Affiliation Narayana Hrudayalaya Ltd
Country India
Scopus ID 57190759680
Documents 6
Citations 173
h-index 4
Subject Area Cancer Biomarkers
Event International Research Awards on, Oncology and Cancer Research

Safeena Kulsum is a researcher affiliated with Narayana Hrudayalaya Ltd in India, with a documented research profile indexed in Scopus under Author ID 57190759680. The supplied profile records six documents, 173 citations, and an h-index of 4, providing a bibliometric basis for describing her scholarly activity. Her stated subject area is Cancer Biomarkers, a field concerned with measurable biological characteristics that can support the understanding and management of disease. Biomarkers may include molecules or molecular signatures detected in tissues, blood, or other biological materials and can contribute to diagnostic, prognostic, and therapeutic decision-making.[1]

Abstract

The Innovative Research Award profile recognizes the documented academic record of Safeena Kulsum in the area of Cancer Biomarkers. The available bibliometric information identifies Narayana Hrudayalaya Ltd as her institutional affiliation and records six Scopus-indexed documents. The supplied metrics further indicate 173 citations and an h-index of 4, which together provide measurable indicators of scholarly visibility within the indexed research record. These indicators are presented descriptively and should be interpreted in relation to publication age, field-specific citation practices, authorship, and database coverage.[2]

Keywords

  • Cancer Biomarkers
  • Oncology Research
  • Molecular Biomarkers
  • Precision Oncology
  • Liquid Biopsy
  • Tumour Biology
  • Cancer Research

Introduction

Cancer biomarkers occupy an important position at the interface of molecular biology, pathology, translational research, and clinical oncology. A biomarker can provide information about a biological process, disease state, treatment response, or other clinically relevant characteristic. The National Cancer Institute notes that biomarkers may be used in understanding disease and evaluating how the body responds to treatment.[1] Their interpretation therefore depends on both biological validity and the context in which testing is performed.

Research Profile

The supplied Scopus record associates Safeena Kulsum with six documents and 173 citations, producing a reported h-index of 4. These metrics offer a concise representation of the indexed publication and citation record available through the supplied author profile. Citation-based indicators are useful for describing research visibility, but they do not independently measure methodological quality, clinical significance, originality, or the practical influence of individual studies. Accordingly, the metrics are best considered alongside publication content and disciplinary context.[2]

Research Contributions

Within the stated field, research contributions may be considered through the development, evaluation, or application of biomarkers that improve understanding of cancer biology. Biomarker investigations can address molecular alterations associated with tumour development, disease progression, therapeutic response, or recurrence. The literature also demonstrates increasing interest in circulating tumour DNA and other liquid-biopsy analytes as tools for longitudinal molecular assessment. These developments emphasize the importance of robust sampling, reproducible laboratory methods, and appropriate clinical validation.[5]

Publications

The supplied Scopus information reports six indexed documents associated with Author ID 57190759680. Because individual publication titles, journal names, publication years, authorship positions, and article identifiers were not supplied, this page does not infer or fabricate a publication list. The Scopus author profile is provided as the primary external source for reviewing the indexed record. Researchers and award reviewers can use that profile to verify individual documents and associated bibliometric information.

Research Impact

The reported citation count of 173 and h-index of 4 indicate that the supplied Scopus record has received measurable scholarly attention. Citation counts can reflect the use of published findings by subsequent researchers, although their interpretation varies considerably between disciplines and publication periods. In cancer research, highly active fields can exhibit different citation patterns from specialized clinical or laboratory areas. Consequently, bibliometric indicators should be interpreted as descriptive evidence rather than as a standalone assessment of research quality.

Award Suitability

The documented research profile is relevant to an academic recognition framework focused on oncology and cancer research because the stated subject area is Cancer Biomarkers. The combination of a defined institutional affiliation, six indexed documents, 173 citations, and an h-index of 4 provides objective bibliometric information for consideration. Award assessment should nevertheless incorporate article-level evidence, research originality, methodological contribution, authorship role, and relevance to the award criteria. These factors help distinguish quantitative visibility from substantive scientific contribution.

Conclusion

Safeena Kulsum is presented here as a researcher affiliated with Narayana Hrudayalaya Ltd, India, with a stated specialization in Cancer Biomarkers. The supplied Scopus record reports six documents, 173 citations, and an h-index of 4 under Author ID 57190759680. These indicators establish a concise bibliometric profile that can support academic recognition while remaining subject to database coverage and periodic updates. More detailed evaluation would require examination of the underlying publications and verified research contributions.

References

    1. National Cancer Institute. (n.d.). Biomarker. NCI Dictionary of Cancer Terms.
      https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
    2. Elsevier. (n.d.). Scopus author details: Safeena Kulsum, Author ID 57190759680. Scopus.
      https://www.scopus.com/pages/authors/57190759680
    3. Valpione, S., Clipson, A., Rothwell, D. G., Dive, C., & Mouliere, F. (2026). Advancing the applications of liquid biopsies in oncology. Nature Reviews Genetics.
      https://doi.org/10.1038/s41576-026-00974-y
    4. Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10, 472–484.
      https://doi.org/10.1038/nrclinonc.2013.110
    5. Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 14, 531–548.
      https://doi.org/10.1038/nrclinonc.2017.14

Kimberly Rieger | Cancer Cell Biology | Innovative Research Award

Published on by Oncology

Innovative Research Award

Kimberly Rieger
Lahey Clinic, United States

              Kimberly Rieger
Affiliation Lahey Clinic
Country United States
Scopus ID 6602699362
Documents 87
Citations 15,323
h-index 33
Subject Area Cancer Cell Biology
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0002-8425

Kimberly Rieger is a cancer researcher associated with Lahey Clinic and the Cell and Molecular Biology research environment at Lahey Hospital & Medical Center. Her published work spans molecular oncology, cancer biology, microRNA regulation, tumor progression, biomarkers, and mechanisms associated with treatment response. [1]

Abstract

The Innovative Research Award profile recognizes Kimberly Rieger-Christ in the context of cancer cell biology and translational oncology research. Her research record includes studies examining molecular regulators of tumor behavior, microRNA-associated pathways, cancer biomarkers, metastatic phenotypes, and mechanisms influencing treatment response. [3] Such research contributes to understanding how molecular alterations can influence cancer progression and clinical outcomes.

Keywords

Cancer Cell Biology; Cancer Research; Molecular Oncology; MicroRNA; Bladder Cancer; Renal Cell Carcinoma; Lung Cancer; Biomarkers; Tumor Progression; Metastasis; Treatment Resistance; Translational Research; Molecular Diagnostics; Oncology.

Introduction

Cancer cell biology investigates the molecular and cellular processes that regulate malignant transformation, proliferation, invasion, metastasis, and response to therapy. Within this field, microRNAs and other regulatory molecules are important because they can influence multiple genes and signaling pathways simultaneously. Rieger-Christ’s published research has addressed these mechanisms across several cancer contexts, particularly urologic malignancies. [5]

Research Profile

The available research record places Rieger-Christ within a multidisciplinary cancer research environment involving molecular biology, genetics, gene expression, cell signaling, and cancer genomics. Her work has included experimental and translational studies addressing bladder cancer, renal cell carcinoma, prostate cancer, and lung cancer.Institutional sources describe research interests that include the molecular basis of genitourinary cancers and the development of improved approaches for diagnosis, prevention, and treatment. [2]

Research Contributions

A recurring contribution in the research record is investigation of microRNA biology in cancer. Published work has examined microRNA profiles associated with gemcitabine resistance in bladder carcinoma cell lines and microRNA signatures associated with invasive disease. [3] These studies address mechanisms that may help explain differences in tumor behavior and therapeutic response.

Publications

Selected publications associated with Kimberly Rieger-Christ demonstrate a sustained focus on molecular oncology. Her work includes studies of microRNA-mediated regulation, cancer invasion, treatment resistance, and molecular characteristics of tumor progression. The Lahey research publication archive records multiple contributions across these areas and provides DOI information for several publications. [3]

  • Kozinn et al. (2013), “MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines.”
  • Das et al. (2023), “The Roles of MiRNAs in Predicting Bladder Cancer Recurrence and Resistance to Treatment.”
  • Kalantzakos et al. (2023), “MicroRNA-155-5p Targets JADE-1, Promoting Proliferation, Migration, and Invasion in Clear Cell Renal Cell Carcinoma Cells.”

Research Impact

Research impact in cancer biology can be assessed through publication continuity, citation activity, methodological relevance, and contribution to clinically meaningful scientific questions. The supplied profile records 87 documents, 15,323 citations, and an h-index of 33. These figures are presented as the profile information supplied for this recognition page and may change as bibliographic databases are updated.The scientific relevance of the work is also reflected in its connection to cancer recurrence, treatment resistance, invasion, metastasis, and biomarker development. . [2]

Award Suitability

The Innovative Research Award is presented here as a recognition framework aligned with research activity in oncology and cancer cell biology. Rieger-Christ’s documented work in molecular cancer mechanisms, microRNA regulation, tumor progression, and translational research provides subject-matter relevance to an international research awards program focused on oncology and cancer research.Award suitability should ultimately be determined through the applicable nomination criteria, supporting evidence, peer or committee assessment, and verification of bibliographic information[2].

Conclusion

Kimberly Rieger-Christ’s research profile reflects sustained engagement with cancer cell biology and molecular oncology, with particular emphasis on microRNA regulation, tumor progression, metastatic phenotypes, treatment resistance, and biomarkers. Her publication record includes research addressing several clinically significant cancer types and molecular mechanisms.Within the context of the International Research Awards on Oncology and Cancer Research, these areas provide a reasonable scholarly basis for consideration under an Innovative Research Award category. The profile should be interpreted alongside current bibliographic records, institutional information, and the formal award evaluation process [3].

References

  1. ResearchGate. (n.d.). Kimberly Rieger-Christ research profile. ResearchGate.
    https://www.researchgate.net/profile/Kimberly-Rieger-Christ
  2. Lahey Hospital & Medical Center. (n.d.). Research: Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/research
  3. Lahey Hospital & Medical Center. (n.d.). Publications of the Ian C. Summerhayes Cell and Molecular Biology Laboratory.
    https://research.lahey.org/icsmb/publications?page=1
  4. Rieger-Christ, K. M., et al. (2015). A non-invasive miRNA based assay to detect bladder cancer in cell-free urine. Asian Journal of Translational Medicine Research.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC4697726/
  5. Elsevier. (n.d.). Scopus author details: Kimberly Rieger-Christ, Author ID 6602699362. Scopus.
    https://www.scopus.com/pages/authors/6602699362

Carlo Croce | Cancer Science | Innovative Research Award

Published on by Oncology

Innovative Research Award

Carlo Croce
Ohio State University, United States

                  Carlo Croce
Affiliation Ohio State University
Country United States
Scopus ID 7202975031
Documents 1,366
Citations 209,103
h-index 213
Subject Area Cancer Science
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-3788-1457

Carlo Croce is a cancer researcher affiliated with The Ohio State University whose research profile is centered on cancer biology, human cancer genetics and molecular mechanisms associated with malignancy. His institutional profile identifies cancer biology as an area of expertise and highlights human cancer genetics and microRNA research as major interests. [1] Bibliographic databases likewise identify his Ohio State affiliation and extensive publication record. [2]

Abstract

The Innovative Research Award recognition profile examines Carlo Croce in relation to contemporary cancer science and molecular oncology. Available institutional and bibliographic records associate his work with cancer biology, human cancer genetics and microRNA-related mechanisms. [1] His documented research activity includes a substantial body of peer-reviewed scientific literature addressing oncogenes, non-coding RNAs and cancer development. [3]

Keywords

Carlo Croce, Innovative Research Award, cancer science, cancer biology, oncology, human cancer genetics, microRNA, oncogenes, molecular oncology, Ohio State University.

Introduction

Cancer research increasingly integrates molecular genetics, cellular biology and translational science to understand how malignant transformation begins and progresses. Croce’s research has addressed molecular alterations associated with cancer, including oncogenes and regulatory mechanisms involving microRNAs. His published review on oncogenes discussed how molecular targets can contribute to the development of targeted anticancer strategies. [3]

Research Profile

The research profile is primarily situated within cancer biology and genetics. The Ohio State University profile identifies Cancer Biology & Genetics as an academic area and specifically lists human cancer genetics and the role of microRNAs in cancer among areas of expertise. [1] Bibliographic records further associate the researcher with a broad body of cancer-related publications and collaborations. [2]

Research Contributions

A significant theme of Croce’s research concerns the relationship between genetic alterations and malignant disease. His work on oncogenes has considered how genes involved in tumor initiation and progression can become relevant therapeutic targets. [3] His research has also examined microRNAs and their regulatory functions, contributing to broader investigation of non-coding RNA biology in cancer. [4]Research involving small non-coding RNAs has extended this molecular perspective into leukemia and related malignancies. A co-authored review published in Cancers examined small non-coding RNAs in leukemia and identified their relevance to cancer biology and potential therapeutic research. [5] These themes demonstrate the integration of molecular genetics with disease-focused oncology research.

Publications

Available scholarly records show an extensive publication history spanning cancer genetics, oncogenes, microRNAs and related molecular oncology topics. The Ohio State research portal lists more than one thousand research outputs associated with the researcher, while the current bibliographic author record identifies a similarly extensive body of indexed work. [2]

  • Oncogenes and cancer, New England Journal of Medicine, 2008.
  • Causes and consequences of microRNA dysregulation in cancer, Nature Reviews Genetics, 2009.
  • Small Non-Coding RNAs in Leukemia, Cancers, 2022. [5]

Research Impact

The supplied research metrics indicate a substantial bibliometric footprint, including 1,366 documents, 209,103 citations and an h-index of 213. Bibliographic information available through the author’s indexed profile confirms a very high level of publication and citation activity, although such metrics can change as databases are updated.Beyond quantitative indicators, the research record reflects sustained engagement with fundamental questions in cancer biology. Publications addressing oncogenes and microRNA regulation have helped frame molecular mechanisms as important components of modern cancer research and therapeutic investigation.

Award Suitability

Based on the supplied profile information, Carlo Croce demonstrates characteristics relevant to an Innovative Research Award in oncology and cancer research. The combination of a long-standing cancer research program, extensive scholarly output, substantial citation activity and research focused on molecular mechanisms provides a strong evidence base for consideration. [1] Final award decisions should remain subject to the event’s formal eligibility criteria and independent review.

Conclusion

Carlo Croce’s academic profile is closely associated with cancer biology, molecular genetics and oncology research. Institutional and bibliographic sources document extensive research activity and a substantial scholarly impact, while representative publications demonstrate sustained work on oncogenes, microRNAs and cancer-related molecular mechanisms. [2] On the basis of the supplied metrics and documented research themes, the profile is relevant to recognition under an innovative cancer research award.

References

  1. The Ohio State University. (n.d.). Carlo Croce — Molecular, Cellular and Developmental Biology Program. Ohio State University.
    https://mcdb.osu.edu/people/croce.5
  2. Elsevier. (n.d.). Carlo Maria Croce — Scopus author details, Author ID 7202975031. ScienceDirect.
    https://www.sciencedirect.com/author/7202975031/carlo-maria-croce
  3. Croce, C. M. (2008). Oncogenes and cancer. New England Journal of Medicine, 358(5), 502–511.
    https://doi.org/10.1056/NEJMra072367
  4. Croce, C. M. (2009). Causes and consequences of microRNA dysregulation in cancer. Nature Reviews Genetics, 10, 704–714.  https://doi.org/10.1038/nrg2634
  5. Balatti, V., & Croce, C. M. (2022). Small Non-Coding RNAs in Leukemia. Cancers, 14(3), 509.
    https://doi.org/10.3390/cancers14030509

mohammad dehghandar | Oncology Alternative Medicine | Innovative Research Award

Published on by Oncology

Innovative Research Award

Mohammad Dehghandar
Payame Noor University

Mohammad Dehghandar
Affiliation Payame Noor University
Country Iran
Scopus ID 57985730600
Documents 3
Citations 5
h-index 1
Subject Area Oncology Alternative Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-4882-3121

The Innovative Research Award article presents an academic overview of Mohammad Dehghandar, a researcher affiliated with Payame Noor University in Iran. The profile summarizes publicly available scholarly information including publication activity, citation metrics, and subject specialization in oncology and alternative medicine. The article is organized in a neutral encyclopedic style suitable for academic recognition and award documentation while providing references to authoritative scholarly databases.[1]

Abstract

This article documents the academic profile of Mohammad Dehghandar for recognition under the Innovative Research Award category. Publicly available bibliometric indicators show contributions indexed within the Scopus database, with research interests associated with oncology and complementary medical approaches. The profile highlights scholarly productivity, research visibility, and measurable citation performance while emphasizing transparent academic evaluation practices based on recognized indexing systems.[2]

Keywords

  • Innovative Research Award
  • Oncology
  • Alternative Medicine
  • Scopus Author
  • Academic Research

Introduction

Academic recognition programs commonly evaluate researchers using publication records, citation metrics, institutional affiliation, and evidence of scientific contribution. These indicators provide an objective basis for assessing scholarly engagement and research influence. The International Research Awards on Oncology and Cancer Research recognize researchers demonstrating meaningful participation within their respective scientific disciplines through transparent evaluation criteria supported by established academic databases.[3]

Research Profile

Mohammad Dehghandar is affiliated with Payame Noor University, Iran. Available bibliographic information identifies three indexed publications with five citations and an h-index of one. These metrics indicate an emerging publication record while reflecting participation in peer-reviewed scholarly communication. The documented research specialization includes oncology and alternative medicine, representing interdisciplinary scientific interests.[1]

Research Contributions

Research contributions are evaluated through peer-reviewed publications, scientific collaboration, and dissemination of evidence-based findings. Bibliometric records suggest participation in oncology-related investigations while contributing to complementary perspectives within medical science. Such activities support the continuous expansion of knowledge and encourage multidisciplinary dialogue in healthcare research.[4]

Publications

Indexed publications provide measurable evidence of scientific productivity and scholarly communication. Publication records available through Scopus enable transparent verification of research output and citation history. Persistent identifiers, including DOI links where available, facilitate long-term accessibility and reproducibility of published scientific work.[5]

Research Impact

Research impact is commonly assessed using citation analysis, publication quality, and academic visibility across recognized indexing platforms. Although citation counts may change over time, standardized databases provide a consistent framework for evaluating scholarly influence. These indicators complement qualitative peer assessment during academic award evaluation processes.[2]

Award Suitability

Based on publicly available bibliometric information, the research profile demonstrates participation in internationally indexed scholarly publishing and aligns with the objectives of academic recognition initiatives. Eligibility for award consideration remains subject to independent committee evaluation, submitted supporting documentation, and compliance with event-specific assessment criteria.[3]

Conclusion

This academic profile summarizes publicly accessible information concerning Mohammad Dehghandar and presents a structured overview suitable for recognition within professional research award documentation. The article follows a neutral, encyclopedic presentation while encouraging readers to consult authoritative databases for the latest bibliometric updates and publication records.[1]

References

  1. Elsevier. (n.d.). Scopus Author Details: Mohammad Dehghandar, Author ID 57985730600.
    https://www.scopus.com/pages/authors/57985730600
  2. ORCID. (n.d.). ORCID Record: 0000-0003-4882-3121.
    https://orcid.org/0000-0003-4882-3121
  3. International Research Awards on Oncology and Cancer Research. (2026). Award Information.
    https://oncology.pencis.com/
  4. International DOI Foundation. (n.d.). Digital Object Identifier System.
    https://doi.org/
  5. Crossref. (n.d.). DOI Registration Agency.
    https://www.crossref.org/